<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03826641</url>
  </required_header>
  <id_info>
    <org_study_id>HM-DAME-101</org_study_id>
    <nct_id>NCT03826641</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects</brief_title>
  <official_title>An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics,
      safety and tolerability of HCP1801 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2019</start_date>
  <completion_date type="Anticipated">March 18, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of Dapagliflozin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Dapagliflozin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Metformin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of Metformin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Dapagliflozin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Dapagliflozin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Dapagliflozin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Dapagliflozin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Dapagliflozin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf of Metformin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Metformin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 of Metformin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of Metformin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F of Metformin</measure>
    <time_frame>pre-dose(0 hour), 0.33, 0.67, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 hour</time_frame>
    <description>pharmacokinetic evaluation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Fasted state + HCP1805, Period 2 : Fasted state + HCP1801</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : Fasted state + HCP1801, Period 2 : Fasted state + HCP1805</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : High fat diet + HCP1805, Period 2 : High fat diet + HCP1801</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 : High fat diet + HCP1801, Period 2 : High fat diet + HCP1805</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1805</intervention_name>
    <description>Dapagliflozin/Metformin (Xigduo XR) 10/1000mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1801</intervention_name>
    <description>Dapagliflozin/Metformin 10/1000mg</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 19~45 years in healthy volunteers

          2. BMI is more than 18.5 kg/m^2 , no more than 29.9 kg/m^2

          3. Subjects who have ability to comprehend the objectives, contents of study and property
             of study drug before participating in trial and have willingness to sign of informed
             consent in writing

        Exclusion Criteria:

          1. Presence of medical history or a concurrent disease that may interfere with treatment
             and safety assessment or completion of this clinical study, including clinically
             significant disorders in digestive system, neuropsychiatric system, endocrine system,
             liver, cardiovascular system

          2. Subjects who judged ineligible by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yirang Lim</last_name>
    <phone>02-410-0339</phone>
    <email>yirang.lim@hanmi.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Ran Yoon, M.D</last_name>
      <email>yry@knu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 28, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

